A Ballarat company that improves the preservation of biological material goes global with a new partnership in the United States.
Vitrafy Life Sciences has partnered with Texas-based BioBridge Global to develop novel cryopreservation systems for human blood services, life-saving cancer treatments and reproductive research.
Brent Owens, one of the co-founders of the Ballarat Company, has spent the last few weeks in the United States to finalize the partnership.
He said he was proud to partner with BioBridge Global.
“Cryopreservation supply chains have not seen technological advancements in decades,” said Mr. Owens.
“A post-COVID world needs better systems in place to ensure that a constant supply of blood products is always available for patients in need.”
Vitrafy Life Sciences was established in 2018, after Ballarat residents Sean Cameron and Brian Taylor and Mr. Owens, originally from Melton, began working to improve food preservation systems for transportation.
They worked to develop algorithms, which are mathematical equations, and a refrigeration solution, to preserve any product at any quantity.
The team moved into the biomedical innovation space after realizing the potential to make life-saving changes with their innovations.
The company is now preparing to go public on the ASX and has quickly expanded its team and partnerships at the Ballarat laboratory.
The team is approaching 20, with three more employees in the coming weeks.
Managing Director Mr Cameron said the point of difference for Vitrafy Life Science was to increase the cryopreservation success rate from 50 percent to over 90 percent, which had not been achieved before. in the world.
Improving survival rates of blood and blood products during storage could prevent blood shortages worldwide.
The technology could also alter the delivery of existing and emerging cell therapies, including cancer treatments.
There is also potential for the development of new products which currently cannot be successfully stored.
Mr Cameron said the BioBridge Global partnership has enabled Vitrafy Life Sciences to begin preclinical trials of cancer treatments that were not currently available in Australia.
He said the partnership would also speed up the regulatory approval process for its technology in the United States.
BioBridge Global is a non-profit organization providing products and services in the areas of blood resource management, cell therapy, umbilical cord blood donation, human tissue, blood testing, plasma and tissue products.
The organization’s senior vice president and medical director Dr Rachel Beddard said the partnership with Vitrafy would bring “changing” technology to America.
“This innovative technology aligns with BioBridge Global’s mission to save and improve lives through the healing power of cells and tissues by improving the cold chain solution for a wide range of our products,” said she declared. Vitrafy Life Sciences is also working with the Royal Women’s Hospital to preserve the ovaries for the first time and the technology is being used by the Red Cross to preserve blood products.
Vitrafy’s algorithm calculates the operating conditions required for cryopreservation of biomaterials and informs the automation software of the precise operating conditions to provide optimal cell survival capacity.